Journal
LANCET
Volume 381, Issue 9869, Pages 845-860Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)61897-2
Keywords
-
Categories
Funding
- European Union
- UK Medical Research Council
- Wellcome Trust
- Association Francaise Contre les Myopathies
- Muscular Dystrophy Campaign
- Great Ormond Street Hospital Biomedical Research Centre
- Muscular Dystrophy Association USA
- GlaxoSmithKline
- Trophos
- British Heart Foundation
- AVI BioPharma
- PTC Therapeutics
- Parent Project NL
- SMA Europe
- Italian Telethon
- MRC [MR/K000608/1] Funding Source: UKRI
- Medical Research Council [MR/K000608/1] Funding Source: researchfish
Ask authors/readers for more resources
Muscular dystrophies are a heterogeneous group of inherited disorders that share similar clinical features and dystrophic changes on muscle biopsy. An improved understanding of their molecular bases has led to more accurate definitions of the clinical features associated with known subtypes. Knowledge of disease-specific complications, implementation of anticipatory care, and medical advances have changed the standard of care, with an overall improvement in the clinical course, survival, and quality of life of affected people. A better understanding of the mechanisms underlying the molecular pathogenesis of several disorders and the availability of preclinical models are leading to several new experimental approaches, some of which are already in clinical trials. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, and therapeutic developments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available